Home Prostate Cancer Biomarkers SelectMDx Test: Urine Gene Markers, Prostate Cancer Risk, and Result Meaning

SelectMDx Test: Urine Gene Markers, Prostate Cancer Risk, and Result Meaning

By
Vita Library
-
4
SelectMDx measures HOXC6 and DLX1 urine gene markers after a prostate exam to estimate clinically significant prostate cancer risk and help guide MRI and biopsy decisions.

SelectMDx is a urine-based prostate cancer risk test that measures messenger RNA from the genes HOXC6 and DLX1 after a prostate-directed digital rectal examination. The molecular result is combined with clinical information to estimate the likelihood of clinically significant prostate cancer, commonly Grade Group 2 or higher. SelectMDx does not diagnose prostate cancer, and it does not replace biopsy when tissue confirmation is needed. Its main purpose is to refine an uncertain biopsy decision after an elevated PSA or other risk signal, potentially helping some men avoid an unnecessary biopsy while identifying others whose risk remains high enough to justify MRI or biopsy. A low-risk result reduces probability but does not reduce it to zero. A high-risk result increases concern but does not prove cancer is present. Test performance varies across studies, and modern decision-making increasingly combines urine biomarkers with prostate MRI, PSA density, family history, prior biopsy findings, age, and patient preferences. The test is most useful when the clinician knows in advance what result would change the next step.

  • SelectMDx measures HOXC6 and DLX1 RNA in urine collected after a prostate-directed exam, rather than measuring PSA in blood.
  • The result estimates risk for clinically significant prostate cancer, not whether cancer is definitely present or absent.
  • A low-risk result can support avoiding or delaying biopsy in selected patients, especially when other findings are reassuring.
  • A high-risk result usually leads to closer evaluation with MRI and/or biopsy, but the result should not be used alone.
  • Correct urine collection matters because the assay depends on prostate-derived material released into the urine after digital rectal examination.

Table of Contents

What SelectMDx Measures

SelectMDx is a molecular urine test designed to improve risk assessment before prostate biopsy. It measures the expression of two messenger RNA markers, HOXC6 and DLX1, which are associated with prostate cancer biology and are expressed at higher levels in many clinically significant tumors.

The test does not look for whole cancer cells under a microscope. Instead, a laboratory measures gene-expression signals from prostate-derived material released into urine after a prostate-directed examination. The molecular information is then combined with clinical variables in a proprietary algorithm to estimate risk.

This is fundamentally different from PSA testing. PSA measures a prostate-associated protein in blood and can rise for cancer and many benign reasons. SelectMDx looks at RNA expression associated with cancer-related pathways. Because the two tests capture different biological information, SelectMDx is generally used after PSA has already raised a question, not as a replacement for routine PSA screening.

The endpoint of greatest interest is usually clinically significant prostate cancer, commonly Grade Group 2 or higher. That matters because many prostate cancers are low grade and may not need immediate treatment. A useful pre-biopsy test should ideally reduce unnecessary biopsies without missing too many cancers that could affect health or survival.

SelectMDx therefore belongs to the same broad family of secondary biomarkers as PHI, 4Kscore, PCA3, ExoDx Prostate, and MyProstateScore. These tests differ in specimen type, molecular targets, algorithms, and evidence base. They should not be treated as interchangeable “cancer panels,” even though they serve a similar clinical purpose.

How the SelectMDx Test Is Done

SelectMDx requires a urine sample collected after a digital rectal examination focused on the prostate. The exam helps release prostate cells, secretions, and RNA into the urethra so they can appear in the first urine passed afterward.

A typical process is:

  1. The clinician reviews PSA, examination findings, family history, prior biopsy status, and other risk information.
  2. A prostate-directed digital rectal examination is performed according to the test protocol.
  3. The patient provides the requested urine sample immediately afterward, usually the initial urine stream.
  4. The specimen is sent to the designated laboratory for molecular analysis.
  5. HOXC6 and DLX1 expression is quantified and combined with clinical variables to generate the risk result.

No fasting is usually required. The important preparation issue is sample timing and technique, not food intake. A random urine sample collected without the required prostate manipulation should not be substituted unless the specific laboratory protocol explicitly allows it.

Tell the clinician about active urinary infection, recent prostate biopsy or surgery, severe urinary retention, or other conditions that may affect the prostate or specimen. The laboratory’s current instructions should take priority because collection requirements can change with assay versions.

Unlike PSA-based blood tests, ejaculation and short-term cycling are not the main analytical concerns for SelectMDx. However, those factors may still influence the PSA that led to testing in the first place, so the overall risk assessment should account for them.

If the urine sample is inadequate, the test may fail or produce an uninterpretable result. Repeating collection may be more appropriate than making a biopsy decision from incomplete molecular data.

How to Interpret SelectMDx Results

SelectMDx is intended to produce a risk estimate, not a diagnosis. A lower-risk result means clinically significant prostate cancer is less likely than it was before testing. A higher-risk result means the probability is higher and further evaluation is more likely to be worthwhile.

The exact report format can vary with test version and region. Some reports provide estimated probabilities for prostate cancer and for clinically significant disease; others emphasize a low-risk or high-risk classification. The most important number is not whether the report uses the word “positive,” but the estimated risk of the clinically relevant endpoint and how that compares with the patient’s tolerance for uncertainty.

A 2024 meta-analysis of 14 publications involving 2,579 patients reported pooled sensitivity of about 81% and specificity of about 52% for SelectMDx, although there was substantial heterogeneity among studies. Another 2023 diagnostic meta-analysis comparing several liquid biomarkers found SelectMDx sensitivity and specificity in the same general range for clinically significant prostate cancer. These values illustrate the tradeoff: the test can identify many significant cancers, but false-positive and false-negative results still occur.

A low-risk result is most reassuring when the rest of the picture is also favorable—for example, stable PSA, low PSA density, normal examination, no strong hereditary risk, and a negative or low-suspicion MRI. If several independent risk factors are concerning, a low SelectMDx result may not be enough to safely avoid biopsy.

Likewise, a high-risk result does not prove cancer. Benign or low-grade findings may still be found on biopsy. The result should be used to update probability, not to label someone as having cancer before pathology is available.

Who May Benefit From SelectMDx

SelectMDx is most useful when a patient and clinician are uncertain about whether the benefit of biopsy outweighs its risks. It adds little when the next step is already obvious.

Potential candidates include men with:

  • a persistently elevated or borderline PSA;
  • a non-suspicious or mildly suspicious digital rectal examination;
  • uncertain risk after considering age and family history;
  • an equivocal MRI lesion, such as PI-RADS 3;
  • a negative MRI but residual concern because PSA density or other features are elevated;
  • a previous negative biopsy with continuing suspicion, depending on local practice and other available tests.

The test may be less useful when MRI shows a highly suspicious lesion and biopsy is already clearly indicated. In that situation, another biomarker may delay a necessary diagnostic step without meaningfully changing the decision.

It may also add little in someone with very low baseline risk who would not choose biopsy even if the molecular score were moderately elevated. A good pre-test conversation should therefore ask: What result would make us biopsy, and what result would make us observe? If neither answer changes management, the test may not be worth ordering.

Health status and life expectancy matter as well. The value of detecting an asymptomatic prostate cancer depends on whether the patient is likely to benefit from treatment during his lifetime. Biomarker testing should not be separated from the same shared decision-making principles used for PSA screening.

SelectMDx Versus MRI and Other Biomarkers

SelectMDx competes and cooperates with several other risk-stratification tools. There is no single best sequence for every patient.

Multiparametric MRI provides anatomical and functional information, shows suspicious lesions, estimates prostate volume, and can guide targeted biopsy. SelectMDx provides molecular risk information from urine. MRI can localize a lesion; SelectMDx cannot. SelectMDx may help decide whether a biopsy is needed; MRI can help decide where to biopsy.

Studies have investigated strategies that use SelectMDx before MRI, after MRI, or together with MRI. The best approach depends on access, cost, local expertise, and the patient’s baseline risk. Combining independent tests can improve discrimination, but stacking tests indiscriminately can also create contradictory results and extra cost.

PHI is a blood test combining p2PSA, free PSA, and total PSA. The Prostate Health Index has a large evidence base and is especially useful in the PSA gray zone.

4Kscore is a blood-based probability model using four kallikreins plus clinical information. It is designed specifically to estimate risk of clinically significant cancer.

PCA3 is another post-exam urine RNA test. It measures PCA3 relative to PSA RNA and historically gained its strongest role in repeat-biopsy decisions. The PCA3 urine test measures a different molecular signal from SelectMDx.

ExoDx Prostate is urine-based but does not require a digital rectal examination and analyzes exosomal RNA. MyProstateScore evaluates urinary molecular markers through a different algorithm.

The 2023 AUA/SUO biopsy guideline supports using adjunctive serum or urine biomarkers when further risk stratification would influence the biopsy decision. It does not require one particular commercial test for all patients.

Limitations and False Results

SelectMDx has several limitations that matter in real-world use.

First, test performance varies across studies. Differences in patient age, PSA range, prior biopsy status, MRI use, biopsy technique, and definition of clinically significant cancer can change sensitivity, specificity, and predictive values. A published negative predictive value from one population cannot simply be transferred to every clinic.

Second, predictive values depend on baseline risk. The same assay performs differently in a low-risk screening population than in a high-risk referral clinic. A “negative” result is more reassuring when pretest risk is already modest.

Third, specimen collection is protocol-dependent. Poor post-exam urine collection or inadequate prostate-derived material can reduce confidence in the result.

Fourth, molecular expression is not perfectly uniform across all cancers. Some clinically significant tumors may not produce a strong HOXC6/DLX1 signal, creating false negatives. Conversely, a high molecular score can occur in someone whose biopsy is benign or only low grade.

Fifth, the test is not a staging tool. It cannot show whether cancer has spread to lymph nodes or bones. If metastatic disease is suspected, imaging such as PSMA PET may be appropriate in a diagnosed cancer setting.

Cost and insurance coverage also vary. A test that does not change the biopsy plan is not clinically efficient even if it is scientifically interesting.

Finally, test algorithms and commercial availability can change. Clinicians should review the current laboratory report rather than relying on a cutoff quoted from an older study or website.

What Happens After the Result

A SelectMDx result should lead to a specific next step based on the combined risk of clinically significant prostate cancer.

If the result is low risk and other findings are reassuring, the patient may choose to defer biopsy and continue PSA follow-up. MRI may be obtained if it has not already been performed, especially when PSA remains elevated. Follow-up should be defined in advance rather than reduced to “come back if something changes.”

If the result is high risk, clinicians often proceed to prostate MRI if not already available, or to biopsy when the combined probability justifies tissue diagnosis. MRI-targeted biopsy can sample suspicious lesions, and systematic cores may be added depending on the clinical setting.

If SelectMDx and MRI disagree, the decision should not be made by simply choosing the test with the scarier result. Review MRI quality, prostate volume, PSA density, family history, digital rectal examination, prior biopsy quality, and the magnitude of the molecular risk estimate. In some cases, another biomarker adds useful information; in others, close surveillance or biopsy is more direct.

A negative test is not a lifetime result. PSA and prostate cancer risk change over time. If PSA rises persistently, the digital rectal examination becomes abnormal, MRI changes, or new hereditary information emerges, the earlier SelectMDx result may no longer represent current risk.

For patients comparing several tests, the broader prostate cancer biomarker panel framework can help clarify which test answers which question. The aim is not to accumulate biomarkers; it is to make a better decision with the fewest necessary tests.

One of the hardest parts of using SelectMDx is choosing an action threshold before the result arrives. If a patient would accept biopsy only when the estimated chance of significant cancer exceeds 20%, for example, a test that moves risk from 12% to 15% may not alter management. The same result could matter to someone who places a very high priority on minimizing missed cancer. Shared decision-making is therefore part of test interpretation, not an optional step after the laboratory report.

The timing of MRI also changes how useful the test may be. If MRI has not yet been performed, SelectMDx can be used as one way to decide who should proceed to MRI or biopsy, depending on the local pathway. If MRI is already negative, the urine result may help estimate residual risk. If MRI is strongly positive, especially with a convincing PI-RADS 4 or 5 lesion, the added value of another pre-biopsy biomarker is often smaller because tissue sampling may already be justified.

Another important distinction is between diagnostic accuracy and clinical utility. A biomarker can have reasonable sensitivity and specificity yet still provide little benefit if clinicians order it in patients whose management would not change. The strongest use case is therefore a genuine decision point where avoiding biopsy has value but missing Grade Group 2 or higher cancer also carries meaningful risk.

If a low-risk SelectMDx result leads to biopsy deferral, the follow-up plan should specify when PSA will be repeated and what changes would trigger MRI, another biomarker, or biopsy. Risk reduction is useful only when it is paired with continued surveillance.

The laboratory result should also be documented alongside the PSA value, prostate volume, MRI findings, and clinical assessment available at the time of testing. That context makes future reassessment more meaningful. If risk factors change months or years later, clinicians can see why biopsy was deferred or recommended and avoid treating an old molecular score as if it were a permanent statement about cancer risk. SelectMDx is most useful when it narrows uncertainty at a specific decision point and is followed by a defined plan.

References

Disclaimer

This article is for general education and does not replace individualized urologic evaluation. SelectMDx result formats, algorithms, availability, and insurance coverage can change, and biopsy decisions depend on PSA, MRI, prostate volume, family history, examination, prior biopsy findings, and personal preferences. Discuss the current laboratory report with the clinician who ordered the test.

RELATED ARTICLESMORE FROM AUTHOR